Find Your Funding Opportunity
HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
Service
|
Source |
Final Application Due Date |
Funding Available
|
Match Required
|
|---|---|---|---|---|
| Health Care |
Federal
HHS |
12-06-2024 | N/A | No Match Required |
-
Service
-
Source
-
Final Application Due Date
-
Funding Available
-
Match Required
Status
- Opportunity Type Discretionary
-
CFDA
93.121 -- Oral Diseases and Disorders Research
93.213 -- Research and Training in Complementary and Integrative Health
93.273 -- Alcohol Research Programs
93.350 -- National Center for Advancing Translational Sciences
93.393 -- Cancer Cause and Prevention Research
93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research
93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
93.865 -- Child Health and Human Development Extramural Research
93.866 -- Aging Research
Description
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.
Eligibility
- IHE
- Local Government
- Non-Profit
- Other
- State Government
- Tribal Government
Additional Eligibility Information
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Key Date(s)
- January 07, 2022: Posted Date
- January 07, 2022: Last Updated Date
- December 06, 2024: Current Closing Date for Applications
- December 06, 2024: Application Due Date
- January 11, 2025: Application Archive Date
Contact Information
NIH OER Webmaster
OERWebmaster03@od.nih.gov